EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vistagen Therapeutics's Enterprise Value is MXN-614.67 Mil.
Vistagen Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-1,219.63 Mil. Therefore, Vistagen Therapeutics's EV-to-FCF for today is 0.50.
The historical rank and industry rank for Vistagen Therapeutics's EV-to-FCF or its related term are showing as below:
MEX:VTGN'
s EV-to-FCF Range Over the Past 10 Years
Min: -35.26 Med: -0.89 Max: 1.03
Current: 0.53
During the past 13 years, the highest EV-to-FCF of Vistagen Therapeutics was 1.03. The lowest was -35.26. And the median was -0.89.
MEX:VTGN's EV-to-FCF is ranked better than 84.59% of 331
companies
in the Biotechnology industry
Industry Median: 15.9
vs MEX:VTGN: 0.53
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vistagen Therapeutics's PE Ratio (TTM) for today is calculated as:
Vistagen Therapeutics's share price for today is MXN10.65.
Vistagen Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-33.626.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VTGN vs PSTV, KYNB, TVGN: EV-to-FCF Comparison
For the Biotechnology subindustry, Vistagen Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's EV-to-FCF falls into.
Vistagen Therapeutics's current Enterprise Value is MXN-614.67 Mil.
Vistagen Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,219.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistagen Therapeutics (MEX:VTGN) has a EV-to-FCF of 0.50 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vistagen Therapeutics and its competitors. According to the industry distribution chart, Vistagen Therapeutics ranks #51 out of 331 companies in the Biotechnology industry, placing it in the top 15.4%.
Is Vistagen Therapeutics' EV-to-FCF too high?
Vistagen Therapeutics' current EV-to-FCF is 0.50. The Biotechnology industry median EV-to-FCF is 15.90. Vistagen Therapeutics' value of 0.50 is 96.9% below this industry median. Based on the distribution chart, Vistagen Therapeutics ranks #51 out of 331 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vistagen Therapeutics has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' EV-to-FCF compare to PSTV and KYNB?
According to the Biotechnology industry distribution chart, Vistagen Therapeutics ranks #51 out of 331 companies for EV-to-FCF. This places Vistagen Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 15.90. Vistagen Therapeutics' value of 0.50 is 96.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.90, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistagen Therapeutics's current EV-to-FCF of 0.50 is 96.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vistagen Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistagen Therapeutics's current EV-to-FCF is 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (MEX:VTGN) has a current EV-to-FCF of 0.50. The stock's GF Value™ is MXN103.67, compared to a current price of MXN10.65 — trading 89.7% below its estimated fair value. The current EV-to-FCF is 0.50 and 96.9% below the Biotechnology industry median of 15.90. Vistagen Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vistagen Therapeutics (MEX:VTGN), the current EV-to-FCF is 0.50 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistagen Therapeutics (MEX:VTGN) Overvalued in 2026?
Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued.
The current stock price of MXN10.65 is trading 89.7% below its estimated GF Value™ of MXN103.67.
Key valuation signals for MEX:VTGN:
EV-to-FCF: 0.50
GF Value™: MXN103.67 vs. price of MXN10.65 (89.7% below fair value)
Industry Position: 96.9% below the Biotechnology median (#51 of 331)
No single metric tells the full story. See the MEX:VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score
Get the complete analysis for MEX:VTGN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VTGN has been successfully added to your 
